MedTrace Logo

A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring

NCT06710470 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 833

Last updated 2024-11-29

No results posted yet for this study

Summary

This observational study aims to assess pregnancy and infant outcomes among pregnant women with psoriasis who have been exposed to deucravacitinib treatment in the USA.

Conditions

Interventions

DRUG

Deucravacitinib

As per product label

DRUG

Systemic psoriasis medications

As per product label

OTHER

No systemic medications

Participants not exposed to any systemic medications

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
15 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-02
Primary Completion
2027-01-31
Completion
2029-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06710470 on ClinicalTrials.gov